Healthcare Global Enterprises Limited has announced a key addition to its senior management team with the appointment of Mr. Pankaj Gautam as Chief Information Officer. The appointment was approved by the Board of Directors at their meeting held on February 05, 2026, following recommendations from the Nomination and Remuneration Committee.

Appointment Details

The regulatory filing submitted under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, confirms that Mr. Gautam will join the company on or before February 15, 2026. He will form part of the Senior Management Personnel of HealthCare Global Enterprises Limited.

Professional Background

Mr. Pankaj Gautam brings extensive experience to his new role, with over 20 years of leadership experience in enterprise-wide transformation across major healthcare organizations. His expertise spans multiple critical areas of healthcare technology and operations.

Key Areas of Expertise

• Digital health and technology strategy
• Operational leadership in healthcare settings
• Technology-enabled care model scaling
• Integrated Health Delivery Networks
• Enterprise HIS/EMR-EHR platforms

Previous Experience

Gautam has held leadership positions at several prominent healthcare organizations, where he has driven significant technological initiatives. His career includes tenures at Rainbow Children's Hospitals, Glenhealth Works, and Apollo, where he led high-impact transformation projects.

Regulatory Compliance

The appointment follows all regulatory requirements under SEBI LODR Regulations. The company has filed the necessary disclosures with both the National Stock Exchange of India Limited and BSE Limited, ensuring full compliance with listing obligations. The detailed information has been provided in accordance with Regulation 30(6) and the SEBI Master Circular dated January 30, 2026.

Healthcare Global Enterprises has released its Q3FY26 financial results through an investor presentation, demonstrating robust operational performance with strong revenue growth and significant EBITDA expansion across its pan-India oncology network. The company achieved broad-based growth across all three key clusters while maintaining margin expansion despite reporting a net loss.

Financial Performance Overview

The company delivered strong financial metrics in Q3FY26, with revenue reaching ₹6.33 billion compared to ₹5.59 billion in Q3FY25, representing growth of 13% year-on-year. Adjusted EBITDA performance was particularly impressive, growing 20% to ₹1.11 billion from ₹923 million in the corresponding quarter of the previous year.

Regional Performance Highlights

Healthcare Global Enterprises achieved broad-based growth across its three key regional clusters during Q3FY26. The West cluster, representing 45% of revenue, delivered the strongest performance with 17% year-on-year revenue growth supported by strong volumes across all hospitals including the ramp-up of the expanded hospital in Ahmedabad.

Nine-Month Performance and Operational Metrics

For the nine months ended December 2025, Healthcare Global Enterprises reported revenue of ₹18.93 billion compared to ₹16.38 billion in the corresponding period of the previous year, reflecting growth of 15%. The company's adjusted EBITDA for nine months reached ₹3.46 billion, up 20% from ₹2.89 billion in the previous year, with margins expanding to 18.3% from 17.7%.

Strategic Developments and Leadership Strengthening

The company has completed senior leadership augmentation across key functions including marketing, domestic sales, international business, finance, technology, and clinical strategy. Healthcare Global Enterprises is also advancing its North Bangalore Greenfield Hospital project, which will be the first in Bangalore to offer MR-LINAC technology, with operations expected to commence by the end of Q4FY26.

Profitability and Net Loss Position

Despite strong operational performance, Healthcare Global Enterprises reported a consolidated net loss of ₹94 million in Q3FY26 compared to a profit of ₹70 million in Q3FY25. The company noted that Q3FY26 PAT was impacted by higher depreciation and interest expenses from growth investments and acquisitions, along with an exceptional item of ₹127 million related to changes in gratuity provisions under new labor codes.